Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risedronate for bone morbidity in fibrous dysplasia
NL-OMON32720Phase 3Withdrawn
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in fibrous dysplasia comparing Risedronate with Placebo (2 arms). Primary endpoints: Bone pain intensity, Safety and tolerability and 1 more. Planned start Nov 2008; status: withdrawn.
02
Drugs
risedronate
03
Conditions
fibrous dysplasia
Beyond the preview
Go deeper on NL-OMON32720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32720.